100% agree this would be the best solution. Unfortunately in almost all African Countries, perceived sovereignty and not “bowing the knee” to the West is put at far higher premium than things like drug approvals. This would be scoffed at accross the continent for this reason.
To be fair it’s not like high income country’s are doing great at getting their approvals sorted, partly for similar pride reasons.
Yes, sadly I think you’re right, and the fact that this would be a good policy for Western countries also probably makes little difference in the rhetorical calculus.
I however think it’s important for African countries to have their own independent regulatory authorities because we’ve seen examples of first line drugs that work great in the West not necessarily work as efficiently for African populations, for example in antihypertensives, anti failure drugs etc. I thus believe African countries developing their own health data is key in the long run and a focus on streamlining market accessibility for new drugs THAT WORK FOR AFRICAN POPULATIONS is key.
100% agree this would be the best solution. Unfortunately in almost all African Countries, perceived sovereignty and not “bowing the knee” to the West is put at far higher premium than things like drug approvals. This would be scoffed at accross the continent for this reason.
To be fair it’s not like high income country’s are doing great at getting their approvals sorted, partly for similar pride reasons.
Yes, sadly I think you’re right, and the fact that this would be a good policy for Western countries also probably makes little difference in the rhetorical calculus.
Hi Nick,
I do get the “perceived sovereignty” angle.
I however think it’s important for African countries to have their own independent regulatory authorities because we’ve seen examples of first line drugs that work great in the West not necessarily work as efficiently for African populations, for example in antihypertensives, anti failure drugs etc. I thus believe African countries developing their own health data is key in the long run and a focus on streamlining market accessibility for new drugs THAT WORK FOR AFRICAN POPULATIONS is key.